Tanggung Jawab Hukum Bagi Produsen Obat Sirup Anak yang Berbahan Zat Berbahaya Berdasarkan Undang-Undang No 17 Tahun 2023 Tentang Kesehatan

Authors

  • Mohammad Ginong Pratidina Universitas 17 Agustus 1945 Semarang

DOI:

https://doi.org/10.62383/referendum.v1i2.35

Keywords:

Syrup Medicine, Producers, Health Act

Abstract

The case shows that some children's syrup drug products contain hazardous substances that can endanger the health of children. As a producer of children's syrup, their legal responsibility is very important in ensuring consumer safety. Law No. 17 of 2023 concerning Health provides a legal framework that regulates the responsibility of producers in this regard. This thesis discusses the legal responsibility of producers of children's syrup containing dangerous substances based on the law. The research reviews legal aspects related to producer responsibility, including legal sanctions that can be given to producers if they are found to have violated regulations, as well as what efforts producers can take to minimize legal risks and meet product safety and quality standards. The results of the study show that manufacturers of syrup for children must pay attention to various regulations and safety and quality standards stipulated by Law No. 17 of 2023 concerning Health and related institutions, and conduct product trials periodically to ensure safety and quality. In addition, producers must also be prepared to face legal sanctions if they violate existing regulations, such as fines and revocation of business licenses. The legal responsibility of the producer, then legal liability, namely civil, criminal and administrative responsibility Legal efforts that can be carried out Mediation efforts with the business actor/manufacturer of children's syrup medicine, if this fails, then the process can be carried out through the Consumer Dispute Protection Agency (BPSK), if the decision is not satisfactory, further legal action can be taken through the general court. The Ministry of Health and BPOM should be able to mitigate risks at the outset, regarding the distribution of drugs in Indonesia

 

 

Downloads

Download data is not yet available.

References

Amiruddin. (2017). Pengantar Metode Penelitian. Jakarta: Raja Grafindo Persada.

CNBC Indonesia. (2022, December 26). Obat sirup berbahaya: 324 anak meninggal, BPOM digugat. Diakses dari https://www.cnbcindonesia.com/lifestyle/20221226174054-33-400254/obat-sirup-berbahaya-324-anak-meninggal-bpom-digugat

CNN Indonesia. (2022, October 24). 141 anak meninggal, kasus akibat gagal ginjal Indonesia lampui Gambia. Diakses dari https://www.cnnindonesia.com/gaya-hidup/20221024173057-255-864727/141-anak-meninggal-kasus-akibat-gagal-ginjal-indonesia-lampaui-gambia

Detik Health. (2022, Month Day). Jejak baru kasus gagal ginjal: Pelarut obat dioplos EG, DEG hingga 90%. Diakses dari https://health.detik.com/berita-detikhealth/d-6397299/jejak-baru-kasus-gagal-ginjal-pelarut-obat-dioplos-eg-deg-hingga-90-persen

Katno, P. S. (2017). Tingkat Manfaat dan Keamanan Tanaman Obat dan Obat Tradisional. Yogyakarta: Universitas Gadjah Mada.

Kompas. (2022, October 22). Beredar daftar 102 obat sirup yang disebut dilarang dijual di apotek. Diakses dari https://www.kompas.com/tren/read/2022/10/22/162900065/beredar-daftar-102-obat-sirup-yang-disebut-dilarang-dijual-di-apotek-ini?page=all

Kontan. (n.d.). Bukan 69, BPOM perbarui daftar obat sirup berbahaya dan dilarang beredar, tambah 4. Diakses dari https://kesehatan.kontan.co.id/news/bukan-69-bpom-perbarui-daftar-obat-sirup-berbahaya-dan-dilarang-beredar-tambah-4

Noviyanti, N. K. A. (2017). Tanggung jawab pelaku usaha atas penggunaan obat tradisional yang mengandung bahan kimia obat. Jurnal Kertha Semaya, 01(03).

POM. (n.d.). Penjelasan BPOM RI tentang isu obat sirup yang berisiko mengandung cemaran etilen glikol (EG) dan dietilen glikol (DEG). Diakses dari https://www.pom.go.id/new/view/more/klarifikasi/157/Penjelasan-BPOM-RI-Tentang-Isu-Obat-Sirup-yang-Berisiko-Mengandung-Cemaran-Etilen-Glikol--EG--dan-Dietilen-Glikol--DEG-.html

Pratama, I. P. R. (2021). Pelaksanaan perlindungan konsumen obat-obatan dalam kefarmasian. Jurnal Warmadewa, 2(1).

Soekanto, S. (2013). Pengantar Penelitian Hukum. Jakarta: Universitas Indonesia Press.

Tarigan, A. E. (2022). Tanggung jawab pelaku usaha memproduksi obat sirup cair menimbulkan gagal ginjal akut pada anak. Jurnal Surya Kencana Dua, 9(2).

Triwibowo, C. (2018). Etika dan Hukum Kesehatan. Yogyakarta: Nuha Medika.

UGM. (n.d.). Guru Besar UGM beri tanggapan soal penggunaan obat sirup yang diduga picu gagal ginjal. Diakses dari https://www.ugm.ac.id/id/berita/23082-guru-besar-ugm-beri-tanggapan-soal-penggunaan-obat-sirup-yang-diduga-picu-gagal-ginjal

Published

2024-06-21

How to Cite

Mohammad Ginong Pratidina. (2024). Tanggung Jawab Hukum Bagi Produsen Obat Sirup Anak yang Berbahan Zat Berbahaya Berdasarkan Undang-Undang No 17 Tahun 2023 Tentang Kesehatan. Referendum : Jurnal Hukum Perdata Dan Pidana, 1(2), 24–42. https://doi.org/10.62383/referendum.v1i2.35